CN1301254C - Preparation of catifloxacin and purifying method - Google Patents
Preparation of catifloxacin and purifying method Download PDFInfo
- Publication number
- CN1301254C CN1301254C CNB2004100803139A CN200410080313A CN1301254C CN 1301254 C CN1301254 C CN 1301254C CN B2004100803139 A CNB2004100803139 A CN B2004100803139A CN 200410080313 A CN200410080313 A CN 200410080313A CN 1301254 C CN1301254 C CN 1301254C
- Authority
- CN
- China
- Prior art keywords
- gatifloxacin
- purifying
- preparation according
- acid
- iib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a preparation and purification method for catifloxacin. Cyclized quinolinecarboxylic ester (III) firstly reacts with boric acid and generates chelate (IIb), and the chelate reacts with N-methylpiperazine in the presence of a polar solvent at certain temperature for some time. The mixture is hydrolyzed by a deacidification agent and is respectively processed by acid and diluted alkali, and then catifloxacin white powder is obtained. The obtained catifloxacin has the advantages of good appearance, high purity (which is more than 99.5% through HPLC analysis), high reaction yield and simple refining method, and is suitable for industrial production.
Description
Technical field
The present invention relates to i.e. (±)-1-cyclopropyl-6-fluoro-1 of Gatifloxacin, 4-dihydro-8-methoxyl group-7-(3-methyl isophthalic acid-piperazine)-4-oxo-3-quinoline carboxylic acid's preparation and purification process.
Background technology
Gatifloxacin (gatifloxacin, AM-1155,1), i.e. (±)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxyl group-7-(3-methyl isophthalic acid-piperazine)-4-oxo-3-quinoline carboxylic acid is a kind of new quinolones antiseptic-germicide, has the advantages that spectrum is efficient, phototoxicity is low.
Existing Gatifloxacin preparation technology all will make quinoline carboxylic acid's cyclized ester (III) earlier, makes Gatifloxacin (I) from quinoline carboxylic acid's cyclized ester (III) again.By quinoline carboxylic acid's cyclized ester (III) preparation Gatifloxacin (I) two kinds of approach are arranged: (1) first method is to get quinoline carboxylic acid's cyclocomplex (IIa) by (III) first hydrolysis, obtains Gatifloxacin (I) with the N methyl piperazine condensation again.Since 8 methoxyl groups push away electronic action by force, make 7-position F reduce greatly as the leavings group activity of nucleophilic substitution reaction, when therefore making (I) by (III), yield is the end of than, only about 20% (referring to EP241206).(2) second method is to form inner complex (IIb) (referring to EP241206) with acid reaction earlier by (III), makes Gatifloxacin (I) with the N methyl piperazine reaction again.
Summary of the invention
The object of the present invention is to provide a kind of method of easy and simple to handle, yield is higher, outward appearance good and product purity is high production Gatifloxacin.
Purpose of the present invention can realize by following technical measures:
In the method for preparation of the present invention and purifying Gatifloxacin, form inner complex (IIb) with acid reaction earlier by quinoline carboxylic acid's cyclized ester (III), again with N methyl piperazine in the presence of polar solvent at a certain temperature the reaction (temperature of reaction is preferably 70-80 ℃, more preferably 78 ℃) for some time (being preferably 2-5 hour, more preferably 3 hours).Use de-acidying agent (being hydrolytic reagent) hydrolysis then as triethylamine, pyridine, to dimethylamino pyridine or dimethyl formamide (DMF).The selective hydrolysis reaction times is 7-13 hour, more preferably 10 hours.Handle respectively with acid and diluted alkaline again, obtain the Gatifloxacin white powder.Gained Gatifloxacin outward appearance is good, purity height (HPLC analyze reach more than 99.5%), and reaction yield higher (totally 52.2%), process for purification is easy, is suitable for suitability for industrialized production.
In the method for the invention, described preferred polar solvent is acetonitrile, dimethyl sulfoxide (DMSO) (DMSO), DMF, tetrahydrofuran (THF) or methylene dichloride, more preferably acetonitrile.
In a preferred embodiment of the invention, preferred hydrolytic reagent be triethylamine, pyridine, to dimethylamino pyridine or DMF.
In a preferred embodiment of the invention, preferred acid is hydrochloric acid, sulfuric acid, phosphoric acid or acetic acid, more preferably concentrated hydrochloric acid.
In a preferred embodiment of the invention, preferred diluted alkaline is sodium hydroxide or potassium hydroxide solution, more preferably the solution of 5-8%, most preferably 5% sodium hydroxide solution.
The present invention is simple to operate, and product appearance is good, and yield is higher, especially can obtain the Gatifloxacin of high purity (it is more than 99.5% that HPLC analyzes).
Embodiment
Embodiment 1.
In the 250ml reaction flask, add Zinc Chloride Anhydrous 0.4g, diacetyl oxide 120ml, be heated to 80 ℃, add boric acid 13.2g then, temperature is controlled at 80-110 ℃, finishes in batches, under 110 ℃ of temperature, stirred 1 hour, and be cooled to 80 ℃ then, add compound (III) 60g and reacted 2 hours with 80 ℃.Reaction finishes, the reclaim under reduced pressure diacetyl oxide has solid to separate out to bottle, is cooled to room temperature, add the 350ml absolute ethyl alcohol and stirring, be cooled to below 10 ℃ and make it crystallization, suction filtration, solid is washed till neutrality with frozen water, wash with dehydrated alcohol again, dry that compound (IIb) weighs 55g, yield 70%, outward appearance is a white powder.
Embodiment 2.
In the 250ml reaction flask, add compound (IIb) 55g, acetonitrile 170ml, 2-methylpiperazine 19.5g and triethylamine 56ml, be heated to 60 ℃ of reactions 3 hours, vacuum distillation recovered solvent (the liquid temperature is no more than 60 ℃), debris is diluted with dehydrated alcohol 200ml and is transferred in the reaction flask of 1000ml, add dehydrated alcohol 130ml, water 100ml again, triethylamine 200ml is heated to 76-78 ℃, backflow is arranged, reacted 10 hours, underpressure distillation is to doing, add water 40ml evaporate to dryness again, repeat again once, get grass green liquid.Add dehydrated alcohol 700ml reflux to solid and dissolve fully, cold slightly, add hydrochloric acid to pH=1 under stirring, have solid to separate out, filter, solid is washed back 360ml water heating for dissolving with dehydrated alcohol, the sodium hydroxide of 60 ℃ of Dropwise 5 % makes pH=8.5, there are a large amount of solids to separate out, filter, wash with cold water and dehydrated alcohol respectively, dry that the white powder solid is Gatifloxacin (I), heavy 36.5g, yield is 74.6%, content (HPLC) is 99.6%.
The content assaying method of Gatifloxacin among the present invention:
With octadecylsilane chemically bonded silica is weighting agent; [rare triethylamine solution (1 → 100) is regulated pH to 4.5 with phosphoric acid]-acetonitrile (80: 20) is a moving phase with the triethylamine phosphoric acid solution; 40 ℃ of column temperatures; Flow velocity is 1ml/min; Detect wavelength 325nm.It is an amount of to get the Gatifloxacin reference substance, makes dissolving with an amount of dilute phosphoric acid solution (2 → 1000), adds the biphosphate sodium solution and (gets the NaH of 390mg
2PO
42H
2O is dissolved in water and is diluted to 1000ml) be diluted to the solution that contains 0.5mg among every 1ml approximately, get 20ul and inject liquid chromatograph, the record color atlas; Number of theoretical plate calculates by the Gatifloxacin peak should be not less than 2500.
The reacting flow chart of the inventive method is as follows:
Claims (15)
1. one kind prepares and the method for purifying Gatifloxacin, and this method comprises the following steps: to form inner complex (IIb) with acid reaction earlier by quinoline carboxylic acid's cyclized ester (III),
React for some time at a certain temperature under the condition that polar solvent exists with N methyl piperazine again, use the de-acidying agent hydrolysis then, handle respectively with acid and diluted alkaline again, obtain Gatifloxacin (I) white powder.
2. the method for preparation according to claim 1 and purifying Gatifloxacin is characterized in that described polar solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethyl formamide, tetrahydrofuran (THF) or methylene dichloride.
3. the method for preparation according to claim 2 and purifying Gatifloxacin is characterized in that described polar solvent is an acetonitrile.
4. the method for preparation according to claim 1 and purifying Gatifloxacin is characterized in that described temperature is 70-80 ℃.
5. the method for preparation according to claim 4 and purifying Gatifloxacin is characterized in that described temperature is 78 ℃.
6. the method for preparation according to claim 1 and purifying Gatifloxacin is characterized in that the inner complex (IIb) and the reaction times of N methyl piperazine are 2-5 hour.
7. the method for preparation according to claim 6 and purifying Gatifloxacin is characterized in that the inner complex (IIb) and the reaction times of N methyl piperazine are 3 hours.
8. the method for preparation according to claim 1 and purifying Gatifloxacin, it is characterized in that described hydrolytic reagent be triethylamine, pyridine, to dimethylamino pyridine or dimethyl formamide.
9. the method for preparation according to claim 1 and purifying Gatifloxacin is characterized in that described hydrolytic reagent is a triethylamine.
10. the method for preparation according to claim 1 and purifying Gatifloxacin, the time that it is characterized in that described hydrolysis reaction is 7-13 hour.
11. the method for preparation according to claim 10 and purifying Gatifloxacin, the time that it is characterized in that described hydrolysis reaction is 10 hours.
12. the method for preparation according to claim 1 and purifying Gatifloxacin is characterized in that described acid is hydrochloric acid, sulfuric acid, phosphoric acid or acetic acid.
13. the method for preparation according to claim 12 and purifying Gatifloxacin is characterized in that described acid is concentrated hydrochloric acid.
14. the method for preparation according to claim 1 and purifying Gatifloxacin is characterized in that described diluted alkaline is the solution of the 5-8% of sodium hydroxide or potassium hydroxide.
15. the method for preparation according to claim 14 and purifying Gatifloxacin is characterized in that described diluted alkaline is 5% sodium hydroxide solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100803139A CN1301254C (en) | 2004-09-28 | 2004-09-28 | Preparation of catifloxacin and purifying method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100803139A CN1301254C (en) | 2004-09-28 | 2004-09-28 | Preparation of catifloxacin and purifying method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616456A CN1616456A (en) | 2005-05-18 |
| CN1301254C true CN1301254C (en) | 2007-02-21 |
Family
ID=34765609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100803139A Active CN1301254C (en) | 2004-09-28 | 2004-09-28 | Preparation of catifloxacin and purifying method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301254C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101659654B (en) * | 2008-08-28 | 2013-11-06 | 四川科伦药物研究有限公司 | 2-Methylpiperazine fluoroquinolone compound and preparation method and application thereof |
| CN102351843B (en) * | 2011-08-18 | 2013-07-31 | 张家口市格瑞高新技术有限公司 | Synthesis method of 2-methyl piperazine lomefloxacin |
| CN111777632A (en) * | 2020-07-20 | 2020-10-16 | 浙江国邦药业有限公司 | Preparation method of moxifloxacin hydrochloride chelate |
| CN115819402A (en) * | 2022-12-13 | 2023-03-21 | 无锡福祈制药有限公司 | Preparation method of balofloxacin |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN87103693A (en) * | 1986-03-31 | 1988-03-30 | 三共株式会社 | Quinoline-3-carboxylic acid derivatives and its preparation and application |
-
2004
- 2004-09-28 CN CNB2004100803139A patent/CN1301254C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN87103693A (en) * | 1986-03-31 | 1988-03-30 | 三共株式会社 | Quinoline-3-carboxylic acid derivatives and its preparation and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1616456A (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112552284A (en) | Preparation method of chlorantraniliprole | |
| CN111484524B (en) | Vitamin A acetate intermediate C15 and preparation method of vitamin A acetate | |
| CN102617481A (en) | Preparation method of rosuvastatin calcium | |
| CN102675306A (en) | Preparing method of moxifloxacin or slat thereof | |
| CN101463005A (en) | Method for purifying rebamipide crude product | |
| CN1301254C (en) | Preparation of catifloxacin and purifying method | |
| CN110183445A (en) | The synthetic method of Moxifloxacin and its derivative | |
| CN101323589B (en) | Preparation of novel compound and montelukast sodium | |
| CN102351858A (en) | High selectivity method for synthesizing moxifloxacin | |
| JP3452081B2 (en) | Fluoro-trifluoromethylbenzoic acid derivatives | |
| CN101481350B (en) | Process for synthesizing norfloxacin | |
| CN103665084A (en) | Method for preparing abiraterone acetate | |
| CN110606839A (en) | Green synthesis method of polysubstituted quinazoline derivative | |
| CN108675959A (en) | A kind of deuterated Enrofloxacin-d5Preparation method | |
| CN1660838A (en) | Method for preparing and purifying laevogyrate gatifloxacin | |
| CN101020647B (en) | Synthesis process of beta-cyclopropylamino acrylate | |
| CN103936718B (en) | A kind of preparation method of high-purity delafloxacin | |
| JP6231262B2 (en) | Method for producing a precursor of pitavastatin calcium | |
| CN105777631B (en) | A kind of synthetic method of the bromo- 8- difluoro-methoxies -1,4- dihydroquinoline -3- carboxylic acid, ethyl esters of 1- cyclopropyl -4- oxos -7- | |
| CN101948484B (en) | Method for preparing travoprost intermediate | |
| CN110627721A (en) | Phenanthridine compound and synthesis method thereof | |
| CN105330525A (en) | Preparation method of 7-hydroxy-1-indanone | |
| KR20180011830A (en) | New method for preparation of chromanone derivatives | |
| ZA200503239B (en) | Process for production of an acetylenic compound | |
| CN103936703A (en) | Preparation method of 5-oxaspiro[2,4]heptane-6-one and intermediate thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG DONGYA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANJING SHENGHE PHARMACEUTICAL CO., LTD. Effective date: 20090522 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090522 Address after: Zhejiang Province three counties sea tour town hanging Village Patentee after: Shanghai Youshou Medical Technology Development Co., Ltd. Address before: No. 9 Zhong Hui Road, Nanjing economic and Technological Development Zone, Jiangsu Patentee before: Nanjing Sanhome Pharmaceutical Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: NANJING SANHOME PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHEJIANG DONGYA PHARMACEUTICAL CO., LTD. Effective date: 20121120 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 317100 TAIZHOU, ZHEJIANG PROVINCE TO: 210000 NANJING, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121120 Address after: 210000 No. 9 Zhong Hui Road, Nanjing economic and Technological Development Zone, Jiangsu Patentee after: Nanjing Sanhome Pharmaceutical Co., Ltd. Address before: 317100, Zhejiang Province three counties sea tour town hanging Village Patentee before: Shanghai Youshou Medical Technology Development Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 210038 No. 9 Zhong Hui Road, Nanjing economic and Technological Development Zone, Nanjing, Jiangsu Patentee after: NANJING SANHOME PHARMACEUTICAL CO., LTD. Address before: No. 9 Zhong Hui Road, Nanjing economic and Technological Development Zone Patentee before: Nanjing Sanhome Pharmaceutical Co., Ltd. |